Evidence of comparative efficacy should have a formal role in European drug approvals

BMJ (Online)

Volumn 343, Issue 7822, 2011, Pages

  Sorenson, Corinna ^a   Naci, Huseyin ^a   Cylus, Jonathan ^a,b   Mossialos, Elias ^a,b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DABIGATRAN; NEW DRUG; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; WARFARIN;

BIOEQUIVALENCE; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EUROPE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LICENSING; MEDICAL SOCIETY; METHODOLOGY; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STUDY DESIGN;

DRUG APPROVAL; DRUG INDUSTRY; DRUG TOXICITY; EUROPE; MARKETING;

EID: 84858997018     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4849     Document Type: Review

References (32)

1. The International Conference on Harmonization/Committee for Human Medicinal Products guidelines (CPMP/ICH/364/96) define this as "a pharmacological treatment that is shown to be lifesaving or to prevent irreversible mortality". In this case, non-inferiority comparative trials are required. European Medicines Agency. EU standard of medicinal product registration: clinical evaluation of risk/benefit - the role of comparator studies. EMEA/119319/04. 2004. www.ema.europa.eu/pdfs/human/press/pos/ 11931904en.pdf.
2. Van Luijn JC, Gribnau FW, Leufkens HG. Superior efficacy of new medicines? Eur J Clin Pharmacol 2010;66:445-48.
3. Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labelling. N Engl J Med 2009;361:1230-3.
4. Garattini S, Bertele V. How can we regulate medicines better? BMJ 2007;335:803-5. (Pubitemid 350057261)
5. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005;2:e138.
6. Maio V, Gagne JJ. Impact of ALLHAT publication on antihypertensive prescribing patterns in Regione Emilia-Romagna, Italy. J Clin Pharm Ther 2010;35;55-61.
7. Juurlink DN. Rosiglitazone and the case for safety over certainty. JAMA 2010;304:469-71.
8. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: a systematic review and meta-analysis of observational studies. BMJ 2011;342:d1309.
9. Nissen S. Rosiglitazone: a critical overview. 2010. www.fda.gov/ downloads/AdvisoryCommittees/CommitteeMeetingMaterials/Drugs/ EndocrinologicalandMetabolicDrugsAdvisoryCommittee/UCM218483.pdf.
10. Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, Konig F, Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov 2010;9:277-291.
11. Garattini S, Chalmers I. Patients and the public deserve big changes in the evaluation of drugs. BMJ 2009;338:b1025.
12. Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol 2006;62:610-6. (Pubitemid 44571583)
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
14. Van Luijn JC, Stolk P, Gribnau FW, Leufkens HG. Gap in publication of comparative information on new medicines. Br J Clin Pharmacol 2007;65:716-22. (Pubitemid 351535086)
15. European Social Insurance Platform. Response to the European Commission public consultation on the future of pharmaceuticals for human use in Europe. 2007. www.esip.org/publications/pb139.pdf.
16. Van Luijn JC, Gribnau FW, Leufkens HG. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol 2006;63:159-62. (Pubitemid 46072101)
17. Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA 2011;305:1786-9.
18. Jefferson T, Doshi P, Thompson M, Heneghan C, Cochrane Acute Respiratory Infections Group. Ensuring safe and effective drugs: who can do what it takes? BMJ 2011;342:c7258.
19. Van Luijn JC, Van Loenen AC, Gribnau FW, Leufkens HG. Choice of comparator in active control trials of new drugs. Ann Pharmacother 2008;42:1605-12.
20. Chokshi DA, Avorn J, Kesselheim AS. Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood) 2010;29:1842-8.
21. Gage BF. Can we rely on RE-LY? N Engl Med J 2009;361:1200-2.
22. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009;151:206-9.
23. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32. (Pubitemid 37430387)
24. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147.
25. Fleurence RL, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood) 2010;29:1826-33.
26. European Medicines Agency. Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more are available. EMA/759784/2010. November 2010.
27. European Commission. Final conclusions and recommendations of the High Level Pharmaceutical Forum. 2008. http://ec.europa.eu/pharmaforum/docs/final- conclusions-en.pdf.
28. Gagne JJ, Choudhry NK. How many "me-too" drugs is too many? JAMA 2011;305:711-2.
29. European Medicines Agency. Road map to 2015: The European Medicines Agency's contribution to science, medicines and health. 2010.
30. Garattini S, Bertele V. Europe's opportunity to open up drug regulation. BMJ 2010;340:c1578.
31. Chan A. Access to clinical trial data. BMJ 2011;342:d80.
32. Barbui C, Baschirotto C, Cipriani A. EMA must improve the quality of its clinical trial reports. BMJ 2011;342:d2291.